Distinguished Staff Scientist (Cancer Biology and Radiopharmaceutical Therapy Development and Advanc

Oak Ridge National Laboratory•Oak Ridge, TN

12d•Onsite

About The Position

Join Oak Ridge National Laboratory (ORNL), in collaboration with the University of Tennessee (UT) Oak Ridge Innovation Institute (ORII) Convergent Research Initiative, as we advance radiopharmaceutical therapies. The position will be with the Isotope Applications Research Group (IARG) within the Radioisotope Science and Technology Division. We seek a Distinguished staff scientist with expertise in cancer cell biology and radiobiology to strengthen preclinical therapeutic evaluation, connect tumor biology with radiopharmaceutical development, and support translation of promising approaches toward clinical application. The research will focus on advancing radiopharmaceutical therapy, with emphasis on tumor biology and preclinical radiobiology. Areas of interest include: Mechanistic studies of tumor response to radiation and targeted therapeutics, including DNA damage response, cell-cycle regulation, signaling, resistance, and radiosensitization. Development and use of mammalian cancer model systems, including 2D and advanced in vitro approaches, to evaluate therapeutic response in relevant tumor contexts. Evaluation of radiopharmaceutical constructs and targeted delivery platforms that support improved tumor targeting, therapeutic efficacy, and safety. Quantitative cellular and molecular assays to assess uptake, viability, cytotoxicity, DNA damage, proliferation, biomarker expression, and off-target effects. Integration of cancer biology with radiochemistry, isotope science, dosimetry, imaging, data analysis, and clinical collaborations to support translation. IARG is a multidisciplinary team dedicated to advancing the production, exploration of fundamental properties, and practical applications of radioisotopes produced at ORNL. Comprised of experts ranging from nuclear engineers and radiochemists to organic chemists and cell biologists, IARG pushes the boundaries of technology in the production, isolation, and characterization of radionuclides. Their work not only enhances our understanding of these isotopes but also explores their current and potential future applications, which include innovations in nuclear battery development, cutting-edge research in next-generation nuclear reactors, and the advancement of targeted alpha therapy in cancer treatment.

Requirements

PhD or equivalent degree in cancer biology, cell biology, molecular biology, biochemistry, pharmacology, biomedical engineering, radiobiology, radiation oncology, or a related field, with 10+ years of relevant experience within the field.
Expertise in cancer biology and one or more related areas such as radiobiology, molecular oncology, therapeutic response assays, molecular imaging, targeted delivery, or radiopharmaceutical therapy.
Strong record of research accomplishments evidenced by publications, presentations, technical contributions, or other impactful work in a relevant field.
Excellent communication skills, capable of conveying complex scientific concepts to diverse audiences.
Ability to obtain and maintain an HSPD-12 PIV badge.
Must be able to obtain and maintain a federal Personal Identity Verification (PIV) card.
Successful candidates must be qualified for access without an export control license.

Nice To Haves

Experience with advanced cancer model systems and quantitative cellular or molecular assays used to evaluate therapeutic response, mechanism of action, or radiosensitization.
Familiarity with radionuclide or radiopharmaceutical therapy research, targeted delivery or nanomedicine approaches, dosimetry-informed studies, combination therapy strategies, or interdisciplinary translational oncology teams.

Responsibilities

Collaborate with researchers across ORNL, UT, and external partners in cancer biology, radiochemistry, nuclear medicine, radiobiology, medical physics, and clinical oncology.
Conduct research in tumor biology, radiobiology, and therapeutic evaluation to improve targeting, efficacy, and understanding of therapeutic response.
Work with university and clinical partners to help move promising radiopharmaceutical and combination therapy concepts from preclinical studies toward clinical applications.
Seek external funding opportunities and assist in securing research grants, contracts, and philanthropic support to sustain and expand research activities.
Publish findings in peer-reviewed journals, present at scientific conferences, and engage in outreach activities that enhance the visibility of ORNL, UT, and ORII.
Assist in mentoring graduate students and interns, offering guidance, support, and professional development opportunities to cultivate a skilled research team.